Abstract:Aim: Cancer as a complex disease poses significant challenges for both diagnosis and treatment. Researchers have been exploring various avenues to find effective therapeutic strategies, with a particular emphasis on cellular signaling pathways and immunotherapy. One such pathway that has recently been suggested is the PD-1/PD-L1 pathway, which is an immune checkpoint signaling system that plays an important role in regulating the immune system and maintaining tissue homeostasis. Cancer cells exploit this pathway by producing PD-L1, which attaches to PD-1 on T cells, thus inhibiting immune responses and enabling the cancer cells to escape detection by the immune system. This study aimed to evaluate the role of the PD-1/PD-L1 pathway in cancer pathogenesis and treatment. Method: This study was performed based on the principles of Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). All in vitro , in vivo , and clinical studies that were published in English have been considered during a thorough search of the Scopus, Web of Science, and PubMed databases without date restriction until March 2024. Results: According to the studies reviewed, the PD-1/PD-L1 signaling axis suggests promising therapeutic effects on various types of cancers such as non-small cell lung cancer, melanoma, breast cancer, hepatocellular carcinoma, squamous cell carcinoma, and colorectal cancer, among others. Additionally, research suggests that immune checkpoint inhibitors that block PD1/PD-L1, such as pembrolizumab, atezolizumab, nivolumab, durvalumab, cemiplimab, avelumab, etc. , can effectively prevent tumor cells from escaping the immune system. Moreover, there might be a possible interaction between microbiome, obesity, etc. on immune mechanisms and on the immune checkpoint inhibitors (ICIs). Conclusion: Although we have gained considerable knowledge about ICIs, we are still facing challenges in effectively prescribing the appropriate ICIs for individual patients. This is largely due to the complex interactions between different intracellular pathways, which need to be thoroughly studied. To resolve this issue, it is necessary to conduct more reliable clinical trials that can produce a scientific consensus.

PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders

The Nuclear Transportation of PD-L1 and the Function in Tumor Immunity and Progression

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

PD-1 regulation in immune homeostasis and immunotherapy

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Generation, secretion and degradation of cancer immunotherapy target PD-L1

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

PD-1/PD-L1 pathway: current researches in cancer.

Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy

Regulatory mechanisms of PD-1/PD-L1 in cancers

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications

Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges

Post-translational Modification of PD-1: Potential Pathways for Cancer Immunotherapy

PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy

The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment: a systematic review